Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. van Campen, K. de Boer, M. Wagenaar, L. Handoko, C. Allaart, A. C. van Rossum, F. de Man, H. J. Bogaard, A. Vonk Noordegraaf (Amsterdam, Netherlands). The effects of beta-blocker therapy on heart rate, symptoms and exercise in pulmonary arterial hypertension. Eur Respir J 2013; 42: Suppl. 57, 4061

Member's Comments

No comment yet.

Related content which might interest you: Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Pulmonary haemodynamics during exercise in patients with pulmonary arterial hypertension Source: Annual Congress 2005 - Exercise testing in pulmonary arterial hypertension Year: 2005 Long-term efficacy of bosentan in treatment of pulmonary arterial hypertension in children Source: Eur Respir J 2011; 37: 70-77 Year: 2011 Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH) Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Changes in exercise haemodynamics during treatment in pulmonary arterial hypertension Source: Eur Respir J 2008; 32: 393-398 Year: 2008 LATE-BREAKING ABSTRACT: Peak oxygen consumption improves in inoperable, but not operable, chronic thromboembolic pulmonary hypertension after treatment with pulmonary arterial hypertension drugs Source: Annual Congress 2013 –New physiologic boundaries Year: 2013 Comparison of exercise capacity and exercise haemodynamic relationships between severe group 3 pulmonary hypertension and pulmonary arterial hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Effect of riociguat on haemodynamic parameters and exercise capacity in patients with chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH) Source: Annual Congress 2009 - Clinical management of pulmonary arterial hypertension Year: 2009 Heart rate recovery in response to disease targeted therapy in pre-capillary pulmonary hypertension Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Riociguat improves excessive exercise ventilation in patients with inoperable chronic thromboembolic pulmonary hypertension Source: Annual Congress 2013 –Pulmonary circulation: chronic thromboembolic pulmonary hypertension, imaging and biomarkers Year: 2013 Open label study of ambrisentan in patients with exercise induced pulmonary arterial hypertension (EiPAH) Source: International Congress 2016 – Pulmonary hypertension and pulmonary embolism: from the bench to the bedside Year: 2016 Adherence to disease-specific drug treatment among patients with pulmonary arterial hypertension or chronic thromboembolic pulmonary hypertension Source: ERJ Open Res, 6 (4) 00299-2020; 10.1183/23120541.00299-2020 Year: 2020 Acute hemodynamic effects of riociguat in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 The influence of fractional pulse pressure on the outcome of pulmonary thromboendarterectomy Source: Eur Respir J 2001; 17: 653-659 Year: 2001 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators Source: International Congress 2015 – Pulmonary hypertension in lung disease Year: 2015 Haemodynamic effects of exercise therapy in stable, optimally treated pulmonary arterial hypertension Source: International Congress 2017 – Exercise and physiology in pulmonary hypertension Year: 2017 Patterns of therapy with sildenafil among patients with pulmonary arterial hypertension (PAH) Source: Annual Congress 2010 - Pulmonary circulation I Year: 2010 Pulmonary arterial hypertension in children Source: Eur Respir J 2003; 21: 155-176 Year: 2003